HER2 Support Group Forums - View Single Post - AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX (

News · 12-03-2007, 08:10 AM

AstraZeneca has announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX (anastrozole) for its licensed breast cancer indications until June 2010.

More...

12-03-2007, 08:10 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,102	AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX ( AstraZeneca has announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX (anastrozole) for its licensed breast cancer indications until June 2010. More...